Opinion

Video

Tazemetostat as Third-line and Beyond Therapy for FL

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Related Videos
David C. Fisher, MD
Yair Lotan, MD, UT Southwestern Medical Center
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.